Patents by Inventor Sunil Kaul
Sunil Kaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10646532Abstract: It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves. The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.Type: GrantFiled: January 29, 2015Date of Patent: May 12, 2020Assignees: National Institute of Advanced Industrial Science and Technology, Kaul-Tech Co., Ltd.Inventors: Renu Wadhwa, Sunil Kaul
-
Patent number: 10520492Abstract: A method to identify target genes or proteins for regulating melanogenesis or pigmentation and to screen for compounds for manipulation of melanogenesis or pigmentation, the method of screening for candidate compounds for regulating melanogenesis or pigmentation, includes bringing test compounds into contact with cells capable of expressing mortalin and/or Hsp60 in vitro, and selecting, from among the test compounds, a compound that changes the expression level of mortalin and/or Hsp60.Type: GrantFiled: April 29, 2014Date of Patent: December 31, 2019Assignees: CHANEL PARFUMS BEAUTE, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Renu Wadhwa, Sunil Kaul, Nobuhiro Ando, Christian Mahe
-
Publication number: 20170007659Abstract: It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves. The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.Type: ApplicationFiled: January 29, 2015Publication date: January 12, 2017Applicants: National Institute of Advanced Industrial Science and Technology, Cyclochem Co., Ltd.Inventors: Renu Wadhwa, Sunil Kaul, Keiji Terao, Yoshiyuki Ishida
-
Publication number: 20160153968Abstract: A method to identify target genes or proteins for regulating melanogenesis or pigmentation and to screen for compounds for manipulation of melanogenesis or pigmentation, the method of screening for candidate compounds for regulating melanogenesis or pigmentation, includes bringing test compounds into contact with cells capable of expressing mortalin and/or Hsp60 in vitro, and selecting, from among the test compounds, a compound that changes the expression level of mortalin and/or Hsp60.Type: ApplicationFiled: April 29, 2014Publication date: June 2, 2016Inventors: Renu WADHWA, Sunil KAUL, Nobuhiro ANDO, Christian MAHE
-
Publication number: 20160113888Abstract: An object of the present invention is to provide a novel drug for treating cancer. The present invention relates to a pharmaceutical composition for treating or preventing cancer which comprises, as an active ingredient, a triethylene glycol of the following formula (I) or a derivative thereof: wherein R1 and R2 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, or —C(?O)R3; and R3 is selected from C1-6 alkyl or C1-6 haloalkyl.Type: ApplicationFiled: June 11, 2014Publication date: April 28, 2016Inventors: Renu WADHWA, Sunil KAUL
-
Patent number: 8591893Abstract: The amino acid sequences of paratope regions involved in internalizing function of an anti-mortalin antibody into tumor cells were determined for the L-chain and H-chain variable regions of cellular internalizing anti-mortalin antibodies and non-internalizing anti-mortalin antibodies. Cancer-cell-specific drug delivery is provided by using the mortalin-binding activity of a single-chain antibody (scFv) wherein L-chain and H-chain variable regions both having the paratope region are linked together via a peptide linker. Also, the sequence of 6 amino acids of an epitope to be recognized by an anti-mortalin antibody having the internalizing function was determined. With the use of an expression vector comprising a nucleic acid that encodes the epitope, an agent for accelerating internalization of a mortalin antibody, a drug bound thereto, and the like into cancer cells is provided.Type: GrantFiled: May 28, 2008Date of Patent: November 26, 2013Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Sunil Kaul, Maki Shiota, Atsushi Inoue
-
Patent number: 8586042Abstract: The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.Type: GrantFiled: December 9, 2010Date of Patent: November 19, 2013Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Sunil Kaul
-
Publication number: 20120302729Abstract: The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.Type: ApplicationFiled: December 9, 2010Publication date: November 29, 2012Applicant: National Institute of advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Sunil Kaul
-
Patent number: 7883702Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: GrantFiled: August 25, 2005Date of Patent: February 8, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Publication number: 20100297664Abstract: The amino acid sequences of paratope regions involved in internalizing function of an anti-mortalin antibody into tumor cells were determined for the L-chain and H-chain variable regions of cellular internalizing anti-mortalin antibodies and non-internalizing anti-mortalin antibodies. Cancer-cell-specific drug delivery is provided by using the mortalin-binding activity of a single-chain antibody (scFv) wherein L-chain and H-chain variable regions both having the paratope region are linked together via a peptide linker. Also, the sequence of 6 amino acids of an epitope to be recognized by an anti-mortalin antibody having the internalizing function was determined. With the use of an expression vector comprising a nucleic acid that encodes the epitope, an agent for accelerating internalization of a mortalin antibody, a drug bound thereto, and the like into cancer cells is provided.Type: ApplicationFiled: May 28, 2008Publication date: November 25, 2010Applicant: NATIONAL INSTITUTE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Renu Wadhwa, Sunil Kaul, Maki Shiota, Atsushi Inoue
-
Publication number: 20080260739Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.Type: ApplicationFiled: August 25, 2005Publication date: October 23, 2008Applicant: NATIONAL INSTITUTE OF ADVANCED IND. SCIENCE AND TEInventors: Renu Wadhwa, Kazunari Taira, Sunil Kaul
-
Publication number: 20080057062Abstract: An object of the present invention is to further examine the functions of the above CARF in detail so as to develop a novel drug through elucidation of such functions. The present invention provides an anticancer agent which comprises an agent for suppressing CARF expression or an agent for inactivating CARF as an active ingredient.Type: ApplicationFiled: July 17, 2007Publication date: March 6, 2008Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Renu WADHWA, Sunil KAUL
-
Publication number: 20060228365Abstract: The invention relates to antibodies that bind to novel polypeptides expressed in immortalized cells, skeletal muscles and undifferentiated cells. In addition, the polypeptides inhibit the differentiation of myoblasts into myotubes.Type: ApplicationFiled: March 21, 2006Publication date: October 12, 2006Inventors: Renu Wadhwa, Sunil Kaul, Roger Reddel
-
Publication number: 20050272126Abstract: A gene expressed specifically in the testis has been unexpectedly isolated in the course of studies of the expression of a gene encoding an unknown protein that triggers cell death. The isolated gene was a novel gene sequence that had no significant homologue in the database. This gene was also found to be involved in the regulation of differentiation in the testis.Type: ApplicationFiled: July 29, 2005Publication date: December 8, 2005Inventors: Takashi Sugihara, Renu Wadhwa, Sunil Kaul, Youji Mitsui
-
Publication number: 20050033036Abstract: A gene expressed specifically in the testis has been unexpectedly isolated in the course of studies of the expression of a gene encoding an unknown protein that triggers cell death. The isolated gene was a novel gene sequence that had no significant homologue in the database. This gene was also found to be involved in the regulation of differentiation in the testis.Type: ApplicationFiled: June 28, 2004Publication date: February 10, 2005Inventors: Takashi Sugihara, Renu Wadhwa, Sunil Kaul, Youji Mitsui
-
Patent number: 6081028Abstract: A thermal conducting material for providing lateral thermal conduction across a surface of an integrated circuit and for enhancing thermal dissipation from the integrated circuit. The integrated circuit is incorporated within a semiconductor device having a cavity package. A layer of the thermal conducting material, preferably electrically non-conductive, is disposed on a surface of an integrated circuit in the form of a die to provide lateral heat conduction to reduce the number of hot spots within the integrated circuit. Alternatively, the thermal conducting, electrically non-conductive material may be used to fill a cavity within the cavity package so that the cavity package dissipates heat in a more effective manner.Type: GrantFiled: August 11, 1995Date of Patent: June 27, 2000Assignee: Sun Microsystems, Inc.Inventors: Ehsan Ettehadieh, Sunil Kaul, Dev Malladi
-
Patent number: 5444296Abstract: A package and packaging technique for enhancing performance of critical chips within an electronic device, wherein the critical chips comprise an integrated circuit. The package includes a main package incorporating a first integrated circuit coupled to a substrate board. At least one package having a second integrated circuit is mounted to the main package in order to reduce (i) propagation delay for data to transfer between critical chips within the main package and one of the plurality of packages or between the critical chips within the plurality of packages and (ii) total footprint area. The method for implementing such a package including the steps of packaging the first and second integrated circuits and electrically coupling these integrating circuits together in a mounted position.Type: GrantFiled: November 22, 1993Date of Patent: August 22, 1995Assignee: Sun Microsystems, Inc.Inventors: Sunil Kaul, Douglas A. Laird